Back to Search Start Over

Plasma Cell-Free DNA Methylomics of Bipolar Disorder With and Without Rapid Cycling.

Authors :
Ho AM
Winham SJ
McCauley BM
Kundakovic M
Robertson KD
Sun Z
Ordog T
Webb LM
Frye MA
Veldic M
Source :
Frontiers in neuroscience [Front Neurosci] 2021 Nov 30; Vol. 15, pp. 774037. Date of Electronic Publication: 2021 Nov 30 (Print Publication: 2021).
Publication Year :
2021

Abstract

Rapid cycling (RC) burdens bipolar disorder (BD) patients further by causing more severe disability and increased suicidality. Because diagnosing RC can be challenging, RC patients are at risk of rapid decline due to delayed suitable treatment. Here, we aimed to identify the differences in the circulating cell-free DNA (cfDNA) methylome between BD patients with and without RC. The cfDNA methylome could potentially be developed as a diagnostic test for BD RC. We extracted cfDNA from plasma samples of BD1 patients (46 RC and 47 non-RC). cfDNA methylation levels were measured by 850K Infinium MethylationEPIC array. Principal component analysis (PCA) was conducted to assess global differences in methylome. cfDNA methylation levels were compared between RC groups using a linear model adjusted for age and sex. PCA suggested differences in methylation profiles between RC groups ( p = 0.039) although no significant differentially methylated probes (DMPs; q > 0.15) were found. The top four CpG sites which differed between groups at p < 1E-05 were located in CGGPB1 , PEX10 , NR0B2 , and TP53I11 . Gene set enrichment analysis (GSEA) on top DMPs ( p < 0.05) showed significant enrichment of gene sets related to nervous system tissues, such as neurons, synapse, and glutamate neurotransmission. Other top notable gene sets were related to parathyroid regulation and calcium signaling. To conclude, our study demonstrated the feasibility of utilizing a microarray method to identify circulating cfDNA methylation sites associated with BD RC and found the top differentially methylated CpG sites were mostly related to the nervous system and the parathyroid.<br />Competing Interests: MF was a consultant (for Mayo Clinic) to Janssen, Mitsubishi Tanabe Pharma Corporation, Myriad, Sunovion, and Teva Pharmaceuticals; none of this funding contributed to any work carried out in this study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Ho, Winham, McCauley, Kundakovic, Robertson, Sun, Ordog, Webb, Frye and Veldic.)

Details

Language :
English
ISSN :
1662-4548
Volume :
15
Database :
MEDLINE
Journal :
Frontiers in neuroscience
Publication Type :
Academic Journal
Accession number :
34916903
Full Text :
https://doi.org/10.3389/fnins.2021.774037